# A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

> **NCT06041269** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AnaptysBio, Inc.** · enrollment: 420 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Rosnilimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06041269
- **Lead sponsor:** AnaptysBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-31
- **Primary completion:** 2024-11-29
- **Final completion:** 2025-05-30
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041269, "A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06041269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*